GIP and Obesity: More recently, dual and triple incretin agonists, targeting combinations of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have achieved even greater weight reductions in clinical trials, raising the prospect of unprecedented efficacy in medical obesity treatment [8,9,10].